GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $42.80 in the latest trading session, marking a +0.28% move from the prior day.
Top Stock Reports for Visa, UPS & TotalEnergies
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), United Parcel Service, Inc. (UPS), and TotalEnergies SE (TTE).
AstraZeneca (AZN) Gets FDA Nod for COVID Prevention Drug
by Zacks Equity Research
With emergency approval from the FDA, AstraZeneca's (AZN) Evusheld is the first cocktail antibody drug approved in the United States to prevent COVID-19 symptoms before virus exposure.
Stock Market News for Dec 9, 2021
by Zacks Equity Research
U.S. stocks closed slightly higher on Wednesday, with major indexes hovering around their record highs, as reports suggested that the Omicron variant of the coronavirus looks less dangerous that it was earlier thought.
Best Income Stocks to Buy for December 9th
by Zacks Equity Research
GSK, BANR, RYN, and SBFG made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 9, 2021.
Stock Market News for Dec 8, 2021
by Zacks Equity Research
U.S. stocks closed higher for the second consecutive session on Tuesday as investors shrugged off fears of the Omicron variant of the coronavirus after reports suggested that the mutant is less severe than originally thought.
Glaxo (GSK), Medicago COVID-19 Jab Effective Against Variants
by Zacks Equity Research
Glaxo (GSK) and Medicago's plant-based vaccine achieves more than 70% efficacy rate against COVID-19 and its major variants.
Anixa (ANIX) COVID Compounds Prove Effective Against Omicron
by Zacks Equity Research
Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.
Sanofi's (SNY) Filing for Rare Disease Drug Accepted by EMA
by Zacks Equity Research
The EMA accepts Sanofi's (SNY) regulatory submission seeking approval for olipudase alfa, a potential treatment for acid sphingomyelinase deficiency.
Roche (RHHBY) Actemra Gets CHMP Recommendation for COVID-19
by Zacks Equity Research
The CHMP recommends EU approval for Roche's (RHHBY) Actemra to treat patients with severe COVID-19.
Merck (MRK) Pauses Enrolment in HIV-1 Prevention Studies
by Zacks Equity Research
Merck (MRK) pauses enrolment for two phase III studies evaluating islatravir for pre-exposure prophylaxis of HIV-1 infection, following the recommendation of an external data monitoring committee.
Bayer's (BAYRY) Phase III Study on Nubeqa Combo Meets Goal
by Zacks Equity Research
Bayer's (BAYRY) phase III study evaluating Nubeqa in combination with docetaxel and androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer meets the primary endpoint.
Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use
by Zacks Equity Research
Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Lilly (LLY) COVID-19 Antibody Gets FDA Nod for Use in Kids
by Zacks Equity Research
With the approval in children and infants, Lilly's (LLY) bamlanivimab with etesevimab can now be given as treatment and prevention options to high-risk individuals of any age.
Best Income Stocks to Buy for December 6th
by Zacks Equity Research
RC, GSK, BNS, and SPG made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 6, 2021.
Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab
by Zacks Equity Research
Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.
GSK vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GSK vs. NVO: Which Stock Is the Better Value Option?
Glaxo (GSK), Vir COVID Drug Appears Effective Against Omicron
by Zacks Equity Research
Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.
Pharma Stock Roundup: FDA Panel Vote for MRK COVID Pill, JNJ Omicron Jab Plan
by Kinjel Shah
FDA panel votes for Merck's (MRK) COVID-19 antiviral pill. AbbVie (ABBV) seeks approval for Skyrizi for Crohn's disease in Europe
Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug
by Zacks Equity Research
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranolone.
Merck (MRK) Vaxneuvance sBLA for Pediatrics Gets Priority Review
by Zacks Equity Research
Merck (MRK) is seeking label expansion for Vaxneuvance for use in pediatric patients aged six weeks through 17 years for the prevention of invasive pneumococcal disease. A decision is expected by on Apr 1, 2022.
AbbVie (ABBV) Files for Skyrizi to Treat Crohn's Disease in EU
by Zacks Equity Research
AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.
AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) sNDA for Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.
Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas
by Zacks Equity Research
Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.